01

Introduction

GLP-1 eligibility starts with the exact product and indication. Wegovy and Zepbound are FDA-approved for chronic weight management in labeled populations; Ozempic and Mounjaro are type 2 diabetes products.

A clinician then checks contraindications, pregnancy plans, diabetes medicines, GI and gallbladder history, eye history, procedures, and whether the expected benefit fits the person's goals.

02

Who the approved weight-management products are for

Wegovy and Zepbound labels describe chronic weight-management use in adults with obesity, or adults with overweight plus at least one weight-related condition, alongside reduced-calorie diet and increased physical activity. Ozempic and Mounjaro have different labeled type 2 diabetes uses. The product name matters before an eligibility discussion begins.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
LIVE CATALOG

Current telehealth prices and providers

These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.

Wegovy injection$1,349 lowest comparable
3 comparable providersVerified 2 August 2026 to 2 September 2026
#1 comparable published price

Pallas Health

Wegovy · Brand-name injection · medication included

Price source · checked 22 August 2026
$1,349a month, continuingVisit provider
#2 comparable published price

GobyMeds

Wegovy® · Weekly injection · medication included

Price source · checked 2 September 2026
$1,695a month, continuingVisit provider
#3 comparable published price

Sprout Health

Wegovy® · Weekly injection · medication included

Price source · checked 2 August 2026
$1,799a month, continuingVisit provider
Open the complete Wegovy comparison
Zepbound injection$1,069 lowest comparable
3 comparable providersVerified 2 August 2026 to 2 September 2026
#1 comparable published price

Pallas Health

Zepbound · Brand-name injection · medication included

Price source · checked 22 August 2026
$1,069a month, continuingVisit provider
#2 comparable published price

GobyMeds

Zepbound® · Weekly injection · medication included

Price source · checked 2 September 2026
$1,399a month, continuingVisit provider
#3 comparable published price

Sprout Health

Zepbound® · Weekly injection · medication included

Price source · checked 2 August 2026
$1,999a month, continuingVisit provider
Different or incomplete price structures
  • Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
Open the complete Zepbound comparison
Ozempic injection$1,299 lowest comparable
2 comparable providersVerified 2 August 2026 to 22 August 2026
#1 comparable published price

Gala Health

Ozempic® · Weekly injection · medication included

Price source · checked 2 August 2026
$1,299a month, continuingVisit provider
#2 comparable published price

Pallas Health

Ozempic · Brand-name injection · medication included

Price source · checked 22 August 2026
$1,299a month, continuingVisit provider
Open the complete Ozempic comparison
Mounjaro injection$1,349 lowest comparable
1 comparable providerVerified 22 August 2026
#1 comparable published price

Pallas Health

Mounjaro · Brand-name injection · medication included

Price source · checked 22 August 2026
$1,349a month, continuingVisit provider
Open the complete Mounjaro comparison

Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.

03

Contraindications that belong at the top of intake

The cited semaglutide and tirzepatide labels list a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and serious hypersensitivity to the product among contraindications. A clinician also reviews prior reactions and the full medication list before selecting a product.

Decision points for GLP-1 Eligibility and Contraindications: What a Clinician Reviews Before Treatment
Decision pointWhat the cited evidence can answer
Exact productConfirm the approved indication, route, and formulation
Outcome evidenceKeep direct trials separate from indirect study comparisons
Practical fitReview safety history, other medicines, follow-up, and access
FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
04

Questions that often change the choice

Diabetes treatment, history of diabetic retinopathy, pancreatitis or gallbladder disease, severe GI disease, kidney-risk symptoms, planned procedures, and pregnancy plans can change the conversation. Tirzepatide labels also include an oral-contraception precaution around treatment initiation and escalation, so that detail needs a product-specific discussion.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
05

Discuss pregnancy and contraception

Labels contain pregnancy-related cautions. Tirzepatide labeling also includes a specific oral-contraception precaution after initiation and escalation.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material PubMed: Clinical study record
06

Review diabetes medicines

Insulin and secretagogues can change hypoglycemia risk. A prescriber may need to reassess the treatment plan before or during GLP-1 care.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material PubMed: Clinical study record
07

Keep price in its place

A cash price, promotion, or provider intake form does not establish clinical suitability. Verify access after the clinical screen.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material PubMed: Clinical study record
08

What the cited sources establish

Eligibility evidence begins with the exact label. Wegovy and Zepbound have weight-management indications, while Ozempic and Mounjaro are diabetes products; their shared class does not erase those distinctions. The labels also make personal or family medullary thyroid carcinoma, MEN 2, and serious hypersensitivity history material to the screening conversation.

The intake also separates clinical eligibility from access. A person can meet a labeled population while facing a coverage, supply, or provider-availability barrier, and a low cash price says nothing about contraindications or expected benefit. The useful outcome of intake is a clear product-specific plan: the condition being treated, the relevant label, the safety questions that need follow-up, and alternatives worth discussing if the first option is a poor fit.

A clear intake also identifies the goal in measurable terms. Weight management, glycemic control, cardiovascular-risk reduction, and kidney-risk reduction overlap for some people but draw on different product labels and evidence. The clinician can then compare the expected benefit with the patient's history, current medicines, and ability to complete follow-up. That is more useful than treating a body-mass threshold or an online intake approval as the whole eligibility decision.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
09

Questions that change the next review

An eligibility intake should make the decision conditions visible: intended indication, diabetes medicines, pancreatitis or gallbladder history, severe GI disease, eye history, pregnancy plans, procedure plans, and all current prescriptions. Coverage and cash price can be discussed after this clinical screen rather than being treated as evidence of suitability.

The choice can change after the first conversation as medical history, medication use, pregnancy plans, or product availability becomes clearer. Product-specific intake facts should be recorded before comparing program terms.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
10

Product details that still need verification

A web checklist cannot verify a contraindication, clear someone for treatment, or resolve a pregnancy, procedure, or drug-interaction question. Labels guide the questions a clinician asks; they do not produce a yes-or-no answer without a full history and the exact product under consideration.

Clinical eligibility and insurance coverage are different decisions. Exact labels matter because indications differ. MTC or MEN 2 history is a listed contraindication on the cited labels. Pregnancy, procedures, eye history, GI history, and co-medications belong in intake. Eligibility is product- and indication-specific. A clinician reviews health history, medicines, pregnancy plans, labeled contraindications, and risks that make one option more or less suitable. The next step is a clinician-led review of the exact product and your situation.

Use the current product label and prompt clinical care for urgent symptoms or medication changes.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
FAQ

Common questions

What does the evidence show about GLP-1 Eligibility and Contraindications: What a Clinician Reviews Before Treatment?
Eligibility is product- and indication-specific. A clinician reviews health history, medicines, pregnancy plans, labeled contraindications, and risks that make one option more or less suitable.
Can I use this as dosing or switching advice?
No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
What should I check before acting?
Check the current product label, the exact formulation, and the plan with the prescribing clinician.
Why are labels named so often?
Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Bottom line

Use evidence to improve the next clinical conversation

Eligibility is product- and indication-specific. A clinician reviews health history, medicines, pregnancy plans, labeled contraindications, and risks that make one option more or less suitable. The next step is a clinician-led review of the exact product and your situation.

Sources

  1. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting GLP-1 eligibility and contraindications.

  2. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting GLP-1 eligibility and contraindications.

  3. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting GLP-1 eligibility and contraindications.

  4. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting GLP-1 eligibility and contraindications.

  5. Clinical study recordPubMed · Accessed 28 August 2026

    Primary evidence supporting GLP-1 eligibility and contraindications.

Refresh triggers

  • A new FDA label or Medication Guide
  • A new major clinical-trial publication
  • An ADA or AGA guideline update
  • A material change to the verified provider registry